cyrilzakka/clinical-trials huggingface dataset:
TRIO CTO (Taiwan Research Initiative on Coronary Total Occlusion)

Coronary chronic total occlusions (CTO) present a significant challenge in the field of interventional cardiology. These complex lesions, characterized by complete blockage of a coronary artery for a prolonged duration, often require specialized techniques and strategies to achieve successful revascularization.

Using this consortium, we will establish a multicenter cohort to evaluate the clinical parameters, angiographic characteristics, interventional techniques, and clinical outcomes involved in coronary CTO intervention. 3 subprojects are listed here.

Subproject 1 intends to develop a novel algorithm integrating antegrade and retrograde scoring system to optimize the CTO intervention and determine the optimal timing for primary retrograde approach. Current algorithm for CTO intervention.

Subproject 2 aims to examine the strategies and outcomes of CTO involving bifurcations. Bifurcation CTO lesions present unique challenges due to their complex anatomy. Opening of the main vessel while preserving important branches is crucial for ensuring favorable long-term clinical prognosis. This subproject will investigate different strategies and devices employed in bifurcation CTO PCI to assess their efficacy and safety outcomes.

Subproject 3 investigates the treatment strategies for right coronary artery (RCA) CTOs with concomitant left main disease, which present a unique and intricate scenario, requiring careful consideration of revascularization strategies.

Eligibility Criteria:
Inclusion criteria

1. Over 20 years old
2. Chronic total occlusion confirmed by coronary angiography, and noted for more than 3 months

Exclusion criteria Nil
A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

The purpose of this study is to compare the effectiveness of different FDA-approved/NCCN-recommended drug treatments for NMIBC. In particular, the FDA-approved drug nadofaragene firadenovec will be compared to usual care with other NCCN-recommended standard treatments for NMIBC (gemcitabine with or without docetaxel, mitomycin, re-treatment with BCG, or pembrolizumab).


Eligibility Criteria:
Inclusion Criteria:

* 21 years of age or older
* Being treated for high-grade NMIBC (Tis, Ta, or T1) with one of the participating treating urologists at MSK
* One or more prior induction course of BCG at any point in time and judgment by the treating urologist that BCG has failed

  °Any amount of maintenance BCG is allowed
* In the previous 12 months, receipt of at least one instillation of any intravesical agent (induction or maintenance) or one administration of systemic therapy for NMIBC treatment

  °An intravesical agent can include BCG or any other NMIBC treatment
* In the opinion of the treating urologist, there is no contraindication to treatment with nadofaragene firadenovec (i.e. hypersensitivity to IFNa, severe immunosuppression) and there is uncertainty over whether nadofaragene is better than "best usual care"

Exclusion Criteria:

* Opting for treatment with radical cystectomy
* Currently enrolled in a clinical trial of an experimental therapy for NMIBC
* Prior exposure to nadofaragene firadenovec
A Study to Evaluate the Safety and Tolerability of LY3000328 in Healthy Participants

The purposes of this study are to determine the safety and side effects of LY3000328, to determine how well the body will tolerate LY3000328, and to determine how long LY3000328 remains in the body.


Eligibility Criteria:
Inclusion Criteria:

* Are overtly healthy males or females, as determined by medical history and physical examination
Changing Habits in Anorexia Nervosa: Novel Treatment Development

The investigators are examining what types of psychotherapy are most helpful for patients as they undergo weight restoration treatment for anorexia nervosa. In this study, patients who are receiving care on our inpatient unit will also receive 4 weeks of one two types of psychotherapy: Supportive Psychotherapy or Regulation Emotions and Changing Habits.

Patients will be receiving specialized inpatient treatment for anorexia nervosa on the Eating Disorders Unit at the New York State Psychiatric Institute, where care is provided free of charge.

Study procedures will begin after one week of acclimating to the inpatient unit. Patients will be randomly assigned to receive either Supportive Psychotherapy (focused on the transition to the inpatient unit) or REACH (focused on changing routines or habits that have become part of the eating disorder). Each treatment consists of 12-sessions, delivered 2-3 times per week.

Before and after treatment, patients will be asked to participate in interviews, questionnaires, and a lunch meal.

Eligibility Criteria:
Inclusion Criteria:

* DSM5 diagnosis of anorexia nervosa
* Age\>= 18
* Medically stable
* Able to provide informed consent

Exclusion Criteria:

* Other psychiatric disorder requiring acute treatment
* Serious medical illness
* Antipsychotic medication
* Severe cognitive impairment
Cryo-ultrasound Versus LASER Therapy on Ankle Sprain in Tennis Players

the effect cryo-ultrasound therapy and LASER therapy on the short-term recovery of tennis players with acute lateral ankle sprains.

Acute lateral ankle sprains are common injuries among athletes, but the optimal treatment strategies in elite athletes are still debated. This proof-of-concept study aimed to assess the impact of cryo-ultrasound therapy and LASER therapy on the short-term recovery of tennis players with acute lateral ankle sprains.

Eligibility Criteria:
Inclusion Criteria:

* Age ranged from 12-16 years.
* elite girls;
* semi-professional tennis players;
* I-II grade lateral ankle sprain injury;
* no persistent instability phenomena or chronic sprains;
* acute injury (within 2 weeks from trauma);
* no evidence of bone edema or skin disorder, once the area of intense pain in motion was delimited, the lack of neurological disturbances was investigated and assessed.

Exclusion Criteria:

* history of recurrent dislocation of the ankle or hyperlaxity of any joint;
* severe rheumatic diseases and/or collagen diseases;
* athletes who have received any form of local physical therapy and NSAIDs within the last 2 months prior to injury;
* athletes who admit to using steroids;
* any contraindication and/or limitation to the use of a physical agent modality (implantable electrophysiological devices, active neoplasms). Taking medications.
* Athletic adult.
Proactive Protection With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19

This study explores whether patients acutely hospitalized may have shorter hospitalization and fewer admittances at Intensive Care Units by treatment with azithromycin and hydroxychloroquine.

In the ongoing coronavirus pandemic, COVID-19, that arose in Wuhan China, there is still sparse data in the course, risk of various complications, and in particular how patients who are hospitalized are best treated to ensure high survival and short hospitalization. Despite the rapid spread of the disease globally, there is no solid data yet to recommend any specific treatments, which is why symptomatic, organ supportive therapy including respiratory therapy in acute pulmonary failure is recommended. There has been reported a high incidence of bacterial super-infections in patients with COVID-19. Patients with COVID-19 also have a higher risk of dying because of septic shock. Thus, there is an urgent need for treatment that can improve the patient's chance of the shortest hospitalization possible, and treatment that can lower the risk of secondary infection and death.

This is a randomized, placebo-controlled, double-blinded multi-center trial evaluating the effect of azithromycin and hydroxychloroquine treatment in patients with COVID-19 during hospitalization. The aim of the study is to investigate whether the treatment can shorten hospitalization, reduce the risk of non-invasive ventilation, admittance to Intensive Care Units and death.

Eligibility Criteria:
Inclusion Criteria:

* Patient admitted to a Danish emergency department, lung medical department or medical department
* Age \>18 years
* Hospitalized \<48 hours
* Positive COVID-19 test/diagnosis during the hospitalization
* Signs informed consent

Exclusion Criteria:

* If the patient uses \> 5 LO2/min at time of recruitment
* Known intolerance/allergy to azithromycin or hydroxychloroquine or hypersensitivity to quinine or 4-aminoquinolinderivates
* Pregnancy
* Breastfeeding
* Neurogenic hearing loss
* Psoriasis
* Retinopathy
* Maculopathy
* Changes in vision field
* Severe liver disease other than amoebiases
* Severe gastrointestinal, neurological or haematological disorders
* eGFR \< 45 ml/min/1.73m2
* Clinically significant cardiac conduction disorders/arrhythmias or prolonged QTc interval
* Myasthenia Gravis
* Uses Digoxin
* Glucose-6-phosphate dehydrogenase deficiency
* Porphyria
* Hypoglycemia at any time since hospitalization
* Severe mental illness which significantly impedes cooperation
* Severe linguistic problems that significantly impedes cooperation
* Treatment with sickle alkaloids
13-valent Pneumococcal Conjugate Vaccine Study in Adults => 50 Years of Age in Mexico

The purpose of this study will be to assess the safety, tolerability, and immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) when given to healthy adults older than 50 years of age who haven't received 23-valent pneumococcal polysaccharide vaccine in Mexico.


Eligibility Criteria:
Inclusion Criteria:

* Male or female older than 50 years of age
* Eligibility must be determined by medical history, physical exam and clinical judgment
* Able to complete an electronic diary
* Available for duration of study
* Negative pregnancy test for subjects in group 2 age 50 to 64 years
* Practice abstinence or use reliable birth control if age is 50 to 64 years

Exclusion Criteria:

* History of allergic reaction to any vaccine
* Previous vaccination with licensed or experimental pneumococcal vaccine
* S. pneumonia infection within past 5 years before investigational product administration
* Known or suspected immunodeficiency or received treatment including cytotoxic agents or systemic corticosteroids, serious chronic disorder such as malignancy cancer
* Receipt of plasma products or immunoglobulins within 60 days
* Bleeding conditions or diathesis
* Receipt of investigational product within 28 days before study entry
* Other severe acute or chronic medical or psychiatric condition
The Effect of a Peer Mentoring Program on Nursing Students

This project is designed as a quasi-experimental study to evaluate the effect of the Peer Leadership Program, established in the Nursing Department, on nursing peer mentor students' empathic self-efficacy, social self-efficacy, and youth leadership characteristics.

The study population comprises second, third and fourth-year students enrolled at Süleyman Demirel University, Faculty of Health Sciences, Department of Nursing, during the 2024-2025 academic year. Peer mentor students, selected on the basis of volunteerism, will be randomly assigned mentors by an independent researcher to ensure randomness. The study will be conducted over a period of six weeks. During this period, the peer mentors will undergo training in communication techniques, interview methods, empathic approach, social motivation and leader-member interaction, with the subsequent sharing of postcasts. Furthermore, a presentation and evaluation meeting will be held between the peer mentors and their mentees, with the aim of fostering empathy and understanding between the two groups. The meeting will be based on the theme of 'nursing and society'. In order to assess the effectiveness of the intervention, the peer mentors' empathic self-efficacy, social self-efficacy and youth leadership characteristics will be evaluated before and after the meeting. Additionally, the socio-demographic data of the students will be recorded in a data collection form.

Eligibility Criteria:
Inclusion Criteria:

* The term "volunteers" is used to designate students enrolled in the 2024-2025 academic year, in their second, third or fourth year of studies, who are actively engaged in the education and training process.

Exclusion Criteria:

* Students who indicated a preference for not being a first-year student and instead volunteered to serve as peer mentors.
Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B

The goal of this clinical study is to learn more about GS-2829 and GS-6779 in healthy participants and participants with CHB.


Eligibility Criteria:
Key Inclusion Criteria:

Phase 1a and 1b:

* Body mass index (BMI) of ≤ 32.0 kg/m\^2.
* Non-diabetic without impaired glucose tolerance.
* No evidence of cardiac disease based on 12 lead ECG.

Phase 1a (Healthy Individuals) only:

* Aged 18 through 60 years.
* No history of Hepatitis B infection with a negative Hepatitis B virus (HBV) core Antibody.

Phase 1b (Virally suppressed CHB individuals):

* Aged 18 through 65 years.
* Documented CHB and HBsAg ≤ 5000 IU/mL at screening.
* No evidence of advanced fibrosis by Fibroscan (defined as Fibroscan \< 9 kPa within 6 months of screening).
* Diagnosed with chronic hepatitis B on suppressive oral antiviral for ≥ 6 months.

Key Exclusion Criteria:

Phase 1a and 1b:

* Use of any systemic antibiotics within 30 days of screening.
* Receipt of any HBV vaccine within 12 months of screening visit or planning HBV vaccination during the study period.
* Receipt of any investigational product within 3 months or vaccine within 3 months of screening (with the exception of influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines, which if needed, should be administered at least 14 days before or after an investigational product administration).
* Receipt of immunoglobulin or other blood products within 3 months of screening.
* Positive serum pregnancy test at screening or positive urine pregnancy on Day 1.
* Have been treated with systemic steroids, immunosuppressant therapies, or chemotherapeutic agents within 3 months prior to screening or is expected to receive these agents during the study (eg, corticosteroids, immunoglobulins, other immune or cytokine-based therapies).
* Participation in any other clinical study (including observational studies) without prior approval from the sponsor is prohibited while participating in the study.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.
EPIRUS FH Reverse Cascade Screening

Familial hypercholesterolemia (FH) is the most common inherited metabolic disorder resulting in marked elevations in low-density lipoprotein cholesterol (LDL-C). If left untreated, lifelong exposure to elevated LDL-C leads to a substantially increased risk of premature cardiovascular disease as compared to the general population. Although FH adverse cardiovascular outcomes are potentially preventable through early identification of FH individuals and initiation of effective treatment, available evidence shows that FH is under-diagnosed and under-treated.

Childhood is the optimal period for FH screening, because due to minimal dietary and hormonal influences, LDL-C levels reflect predominantly the genetic component in children and are well suited to discriminate FH from other causes of elevated LDL-C. If FH remains untreated in this latent stage of the disease, individuals show a 10-fold increase of cardiovascular risk during early and middle adulthood. In this context, an effective approach for detecting FH would be a screening during childhood or in young adolescents in combination with reverse cascade screening of first-degree relatives of FH individuals.

EPIRUS-FH registry is a model program of reverse cascade screening for FH in children and adolescents in Northwest Greece that aims to increase public and physician awareness, strengthen the national registry of familial hypercholesterolemia (HELLAS-FH) and constitute the core for a national FH registry in children and adolescents in Greece.


Eligibility Criteria:
Inclusion Criteria:

* LDL-C \>160 mg/dL on two seperate measurements 3 months apart
* LDL-C \>130 mg/dL + family history of premature coronary artery disease or hypercholesterolemia in one parent
* Children and adolescents on cholesterol-lowering medication

Exclusion Criteria:

* Refusal to sign the consent form and disagreement with the terms of participation.
* Any clinically significant disorder recognized at the time of the preliminary assessment, which in the judgment of the investigator would disqualify patient's participation in the study.
Response Variability to Exercise

In this proposal, the investigators challenge the assumption that following the physical activity guidelines implies benefit for ALL adults, and that if benefit is not achieved in response to first line therapy, it will be by simply exercising more. Thus, for improving cardiorespiratory fitness and cardiometabolic risk factors, unanswered questions include: 1) To what extent, regardless of increasing exercise intensity or amount, is exercise not associated with benefit? Demonstration of a resistance to benefit through exercise in a substantial number of adults would be a novel and important finding, would counter the assumptions of many if not most health care practitioners, and could have immediate and direct application in all health care settings. 2) To what extent will non-responders to first line therapy (150 min/wk) be required to increase exercise intensity or amount to achieve benefit? 3) To what extent will failure to improve CRF segregate (be associate with) with cardiometabolic risk factors? The investigators propose that adults who remain exercise resistant for improvement in CRF and cardiometabolic risk despite increasing amount or intensity are at high risk of metabolic disease and consequently, are candidates for alternative treatment strategies.

The trial has two objectives:

Primary objective: After 16 weeks of first line therapy (150 min/wk of MPA), does increasing exercise intensity or amount for 16 weeks improve cardiorespiratory fitness (CRF, VO2peak) deferentially depending on the CRF response at 16 weeks.

Secondary objective: Determine whether common cardiometabolic risk factors segregate/cluster with respect to variation in CRF to first line therapy in adults, and, whether clinically meaningful improvements in cardiometabolic risk factors segregate with improvement in CRF.

Eligibility Criteria:
Inclusion Criteria:

* Sedentary lifestyle (planned physical activity for one day per week or less).
* Weight stable (± 2 kg) for 6 months prior to the beginning of the study.
* BMI between 20 and 40 kg/m2.

Exclusion Criteria:

* Physical impairment which would make the intervention very difficult or unsafe according to doctor's advice.
* Diabetes, current smokers.
* Plan to move from the area in next 8 months.
Scheduled Intranasal Ketamine

The purpose of this research is to determine if scheduled intranasal ketamine effects opioid requirements in adult trauma patients with moderate to severe pain in the inpatient setting.


Eligibility Criteria:
Inclusion Criteria:

* Patient between aged 18-80 years, present following a traumatic incident, rate pain \> 5 on the numeric rating scale (NSR), and require admission to the hospital.

Exclusion Criteria:

* - Patients that arrive at facility intubated
* Patients that received Ketamine in the field
* Patients less than 18 years old or greater than 80 years
* Pregnant or breast-feeding females
* Hemodynamic instability defined as need for vasoactive drugs or Systolic blood pressure \>180
* Weight less than 80 pounds or greater than 300 pounds
* Glasgow Coma Scale less than 15
* Current acute head injury resulting in unconsciousness
* Current or history of eye injury
* Current or history of seizures
* Facial or nasal fractures that require nasal precautions
* Current or history of intracranial hypertension
* History of Schizophrenia
* BAC (Blood Alcohol Content) greater than 0.08
* Current alcohol abuse
* Current drug abuse or positive drug screen
* Chronic pain or patients on pain contracts
* Inability to assess pain intensity
* Contraindications or allergies to the treatment
* Patients with hepatic insufficiency
* Prisoners
* Nursing home residents
* Urine drug screen positive for illicit drugs or medications not on their home medication list.
* BAC \> 0.08
* Positive pregnancy test
Rescue Intracranial Stenting in Acute Ischemic Stroke

In acute ischemic stroke caused by intracranial large vessel occlusion, rescue intracranial stenting has been recently a treatment option to achieve recanalization in patients with the failure of mechanical thrombectomy. Nevertheless, there are few studies supporting this beneficial treatment in two cerebral circulations. We aimed to analyse whether the use of rescue intracranial stenting would improve prognosis of patients at 3 months.

In Asia population, large intracranial arterial stenosis lesion accounts for more than 30% in common causes of ischemic stroke, compares with about 10% in Caucasian population every year. Normally, in human brain, there are about 130 billion neurons but they are lost equivalent to their losses in approximately 3.6 years of normal aging in case of a large vessel ischemic stroke untreated each hour. Consequently, after the success of 5 randomized controlled trials about the mechanical thrombectomy, which have been done from December 2010 to December 2014, all of guidelines recommended this technique as the first-line treatment in acute ischemic stroke. However, the HERMES meta-analysis showed that revascularisation failure ratio 28.9% in patients older than 80 years. Recently, in case of mechanical thrombectomy failure, many studies suggested the rescue intracranial stenting could be alternative urgently needed treatment to achieve permanent recanalization which is one of the most important factors impacting on clinical outcomes after acute ischemic stroke. Hence, the aims of our study were to assess both the "non-poor" outcome at 3 months and the symptomatic intracerebral hemorrhage relating to procedure in patients receiving rescue intracranial stenting.

Eligibility Criteria:
Inclusion Criteria:

* Evidence of intracranial large vessel occlusion.
* Absence of intracranial hemorrhage.
* Severe stenosis or reocclusion after mechanical thrombectomy.

Exclusion Criteria:

* Tandem lesion.
* Loss to follow-up after discharge.
* A severe or fatal combined illness before acute ischemic stroke.